This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Injunction blocking Edwards-JenaValve deal lauded by US FTC

( January 12, 2026, 18:02 GMT | Official Statement) -- MLex Summary: The US Federal Trade Commission took a victory lap Monday after securing a preliminary injunction to block Edwards Lifesciences from acquiring rival JenaValve Technology. “This is a major victory for the Trump-Vance FTC, American patients, and U.S. healthcare innovation," FTC Bureau of Competition Director Daniel Guarnera said in a statement. "The court’s decision preserves the head-to-head competition between Edwards and JenaValve that has expanded treatment options for patients suffering from potentially fatal heart conditions. Americans win when companies compete to create new and, in this case, lifesaving innovations. The FTC will continue vigorously enforcing the antitrust laws to protect American consumers and improve U.S. healthcare for patients and their families through lower costs, higher quality, and more innovation."See full release....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login